Dengue virus (DENV) infection has a major impact on global public health and current vaccine application is restricted in some countries and only recommended for children older than 9 years. In this study, we have demonstrated that a recombinant measles virus (MV) carried dengue envelope protein domain III (ED3) genes could infect and replicate in the susceptible transgenic mice expressing MV receptor human CD46. After the MV-vectored dengue vaccine immunization, mice developed specific interferon-gamma responses to MV and DENV. Between 4 serotypes of DENV, a dominant DENV-3-specific T-cell response was observed, possibly due to more T-cell epitopes located in DENV-3 ED3 than other serotypes. Neutralizing antibodies against MV and DENV were also induced in the MV-vectored dengue vaccine immunized mice, and protective levels of FRNT50>10 were detected to all serotypes of DENV. We also evaluated the protection against dengue infection. After inoculation with DENV-2, a detectable but significant lower viremia was observed in MV-vectored dengue vaccine immunized mice versus the vector control. In addition, the inflammatory cytokines associated with severe dengue were also significant lower in MV-vectored dengue vaccine immunized mice. Our results with regard to immunogenicity and protection in murine model provide clues for the future application of a 2-in-1 vaccine to against both measles and dengue.
Date:
2019-10
Relation:
European Journal of Immunology. 2019 Oct;49(S3):1051.
